Navigation Links
Drug Patents in India Helping Promote Innovation

President of the Organization of Pharmaceutical Producers of India releases statement on Intellectual Property Day

(PRWEB) April 30, 2010 -- Ranjit Shahani, President of the Organization of Pharmaceutical Producers of India released the following statement on Intellectual Property Day concerning the effect drug patent protection is having on innovation in India:

Emotion tends to override facts when it comes to patents and patients' concerns. Consider the fears stoked when India joined the World Trade Organization in 1995. Many feared drug prices could rise, access to medicines could be reduced and many Indian pharmaceutical companies could close down.

Fifteen years later, these fears have proved unfounded: Drugs in each category are available at multiple price points, accessibility is clearly independent of patents, and Indian companies have become multinationals and entering foreign markets worldwide.

When India reinstated patent protection via IPR (intellectual property rights) reforms, many feared this would lead to decreased access to medicine and delayed entry of generic medicines. Despite the lack of pharmaceutical patents in India for 35 years and some of the lowest prices for medicine in the world, access to medicine in India remained among the lowest in developing nations. In other words, patents have little to do with the ability to access medicines.

While many try to point fingers at drug patents and IPR protection, the lack of healthcare financing and particularly health insurance are the real culprit. Limiting the types of innovations which receive patent protection, as India currently does, won't improve the health of Indians.

Small innovations that build on existing knowledge are the true backbone and a specific strength of the pharma industry. Yet, Indian laws prohibit certain types of pharmaceutical innovations from patent protection, thereby discouraging research. Indeed, this policy hurts Indian patients the most.

There are many meaningful benefits of continued research on existing medicines. For instance, drug formulations and delivery systems can be optimised for greater effectiveness in India's hot, humid climate. Paediatric formulations could be developed for babies suffering from diseases more often found in adults. It could also promote the development of treatment for diseases prevalent in India — tuberculosis, malaria, filariasis and other tropical diseases — where breakthroughs are unfortunately rare.

Innovation, research and patent protection are critical to introducing new drugs into the market. Innovations and effective drugs are inseparable, as diseases constantly mutate and many have inadequate treatments

Without patent protection, innovations decline, as R&D needs immense investments. Due to high, ever-increasing R&D costs, only two in 10 approved medicines earn more than the average cost of developing a new drug. Statistics are telling: a new drug discovery cost around $138 million in 1975, $318 million in 1987 and more than $1.3 billion in 2006.

The Prime Minister, Dr Manmohan Singh, has acknowledged the critical role of innovation at the 97th Indian Science Congress held in Thiruvananthapuram recently: “Our Government has declared 2010-20 as the ‘Decade of Innovations'. We need new solutions in many areas… in healthcare, in energy, in urban infrastructure, in water management, in transportation… The country must develop an Innovation Eco-system to stimulate innovations… And innovative solutions with potential must be nurtured and rapidly applied.”

As we take a look at drug patents on Intellectual Property Day, we must not forget the important role they play in keeping India and the world healthy. With viruses that mutate constantly — HIV/AIDS, H1N1, and TB — incremental innovations are imperative to stay one step ahead in the war against disease. If all innovations are protected to expand treatment options, millions of patients in India and worldwide will benefit. At stake are not just patents, but the lives of millions.

About Organization for Pharmaceutical Producers of India (OPPI)
The Organization for Pharmaceutical Producers of India, established in 1965, is a premier association of research based international and large pharmaceutical companies in India. It also serves as a scientific and professional body. It caters to the needs of Research based Pharmaceutical Industry thereby creating and sustaining an environment conducive to innovation and growth, simultaneously, facilitating industry and stakeholders partnership through various advisory and consultative processes to achieve the Healthcare objectives of the Nation. On the Web at


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Amphora's PatentSafe Electronic Laboratory Notebook Fully Supported on the Apple iPad
2. MindUp (HIRU) Patents in the World Patent Database
3. India Abroad Features Americas Top Ophthalmologist Rajesh Khanna
4. Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones
5. Indianapolis Cosmetic Surgeon One of Few in Indiana Offering Patients Large Volume Liposuction, Brazilian Butt Lift
6. Indian Spice May Thwart Liver Damage
7. The Indiana Clinical and Translational Science Institute (CTSI) Licenses GeneGos Eureka and MetaCore Platforms
8. Long Island Press Investigates Big Tobacco's Lobby to Kill Indian Cigarette Trade
9. Indian Bollywood Masala Sets New Benchmarks in Blogspot World
10. Care improving, cost saving Indiana Network for Patient Care expands
11. Wanted: Indianapolis Customer Service Professionals
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will experience death ... or animal pass away, death lives among us. It is your perspective, however, that ... family of 11 children, author T Sky understands that she may see death more ...
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today that ... Their Ecosystem empowers dentists to make complex business decisions by providing the tools and ... a free fee survey with 10 procedures customized by zip code. , The ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in ... TIGR® Matrix is a long-term resorbable surgical mesh intended to support and reinforce ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability ... to the medical schools of the future. To reach an audience of key ... 2015 ChangeMedEd conference in Chicago, organized by the American Medical Association. , ...
(Date:11/30/2015)... CALIF. (PRWEB) , ... November ... ... ( ), a leading provider of enterprise Time and Attendance/Workforce Management ... status in the Microsoft Partner Program with competencies in the Application Development, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Belgium , Nov. 30, 2015 ... sciences company focused on developing blood-based diagnostic tests for a ... the Company will present at the LD Micro Conference, which ... Los Angeles, CA. Attending from VolitionRx will be ... Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
(Date:11/30/2015)... 2015 Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ... Kentucky Breast Care to increase collaboration with sub-specialists around ... patients. --> Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ...
Breaking Medicine Technology: